Longitudinal Multi-Omics Profiling of Aqueous Humor Implicates GALNS Depletion as a Pro-Fibrotic Mediator of Anti-VEGF Therapy in PDR
简介:
- 作者: Yujuan Huang, Mi Gui, Xiangbin Kong, Taozheng Li, Zikang Xu, Jing Li, Bikun Xian, Yifan Zhang, Xuenan Zhuang, Liang Zhang, Dan Cao
- 杂志: Invest Ophthalmol Vis Sci
- Doi: https://www.doi.org/10.1167/iovs.67.5.43
- 出版日期: 2026/5/18
摘要
Purpose
Preoperative anti-vascular endothelial growth factor (VEGF) therapy in proliferative diabetic retinopathy (PDR) may exacerbate fibrovascular contraction, posing significant challenges. This study aims to characterize proteo-metabolomic changes induced by anti-VEGF therapy, validate key candidates on orthogonal analytical platforms, and provide functional evidence for the lead molecule.
Methods
Aqueous humor from 25 patients with PDR with simple vitreous hemorrhage (VH; n = 13) or VH with tractional retinal detachment (VH + TRD; n = 12) underwent data-independent acquisition (DIA) proteomics and widely targeted metabolomics before and 7 days after intravitreal aflibercept. Molecules altered in both cross-sectional and longitudinal comparisons were classified as “aggravation-type” or “improvement-type.” Aggravation-type molecules were validated by parallel reaction monitoring/selected reaction monitoring (PRM/SRM) in an independent cohort (cataract controls, n = 10; simple VH, n = 5; VH + TRD, n = 5), and GALNS was functionally assessed by siRNA knockdown in fibroblasts.
Results
Intersection analysis identified 38 molecules (5 proteins and 33 metabolites): 35 improvement-type and 3 aggravation-type (CAST, GALNS, and 3-hydroxypropanoic acid [3-HPA]). Independent validation using PRM proteomics and SRM metabolomics confirmed that only GALNS was robustly validated across both cross-sectional (P = 0.016) and longitudinal (P = 0.049) comparisons, whereas CAST and 3-HPA did not reach statistical significance in validation. GALNS exhibited a biphasic pattern—elevated in PDR relative to cataract controls yet depleted in VH + TRD and further declined post-treatment. GALNS knockdown in fibroblasts upregulated α-SMA and collagen I, accelerated migration, and enhanced contractility.
Conclusions
This multi-omics study, reinforced by independent validation, reveals GALNS depletion as a potential pro-fibrotic molecule following anti-VEGF therapy in PDR, offering a promising candidate for perioperative risk stratification. CAST and 3-HPA remain exploratory candidates requiring validation in larger cohorts.
关于派真
作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。
